Preventicus – Stroke prevention starts at the touch of your fingertips

Preventicus – Stroke prevention starts at the touch of your fingertips

Interview with Dr. Thomas Huebner, Founder and Managing Director of Preventicus GmbH.

Following their success in securing an SME Instrument Phase II grant, Dr. Thomas Huebner sat down with us to tell us the story of how Preventicus and Health Tech are enabling us, and our doctors, with greater power over our healthcare decisions, and the impact that working with Catalyze had on getting their innovative managed care concept out to the market.  

Stroke is a major disease that affects the ability of blood vessels to carry oxygen to the brain due to clotting and ruptures. According to the World Health Organization, strokes are globally the second- leading cause of death and the leading cause of complex disability in adults. In Europe, estimates predict that over the next 15 years we will see an increase of 35% of stroke cases due to larger ageing populations. While death rates have been in decline, the costs of caring for stroke survivors is rising due the average lifespan rates rising.

There are two major risk factors of stroke: Hypertension or high blood pressure, and undetected atrial fibrillation, or AF. Approximately one-third of all stroke cases are linked to complications from atrial fibrillation. Atrial fibrillation is not a permanent condition, it comes and goes, and in 50% of the cases you don’t feel anything, and in some cases you only have some accelerated heart rhythm. Due to this unpredictability, it’s highly difficult to diagnose on time.

Yet there is hope, because when atrial fibrillation is diagnosed it can be very effectively treated by using anti-coagulant drugs, which thin the blood and prevent the creation of blood clots. Up to 80% of these strokes are avoidable with early and efficient detection. With the widespread use of smartphones, they have become an easy way to detect heart rate by using the phone camera. However, while the first applications came on the market several years ago measured heart rate, they didn’t measure heart rhythm.

How it all started

I am in the cardiology business for many years so I was aware of this issue of how to find atrial fibrillation in the large population. So I saw an opportunity. We started to use a smartphone application to record heart rhythm frequently to detect AF as accurate as an ECG. Nowadays this has evolved to a managed care program,” said Huebner.

Preventicus takes aim at stroke prevention by creating software for smartphones and smartwatches that keep track of the irregular heartbeats that are a red flag for atrial fibrillation. Yet when they first began, selling the program as a screening alone wasn’t enough.

“When we tried to sell only the screening to insurances, it failed. Doctors in standard care did not know what to do with the patients who were identified from the screening. By standard care they could only offer a 24-hour ECG in most cases, but that is only in 25% able to confirm sporadic (paroxysmal) AF.”

Evolution into a full-scale health care program

While these initial screenings were a vital start, they weren’t quite enough because even when you capture the atrial fibrillation with the camera on your smartphone, or with a smartwatch, it isn’t sufficient information for doctors to make accurate diagnosis, let alone treatment plans. Once Preventicus came into full effect as a full-scale managed care program, they combined screening with smartphones, verification of suspicious findings by a Telecare service, guiding the patients to the closest cardiologist with a 14d ECG patch (to confirm AF with a much higher yield compared to the 24h Holter-ECG in standard care).

“Many people speak about prevention, but not many companies can make it as precise as we do. One part is to then screen for AF, and another part is to confirm AF with a continuous, multi- channel ECG on the chest wall for up to 14 days. For treatment you need as well the quantification of AF, how often the episodes occur, and how long they last.” Dr. Huebner goes on to explain, “The smartphone application takes the pulse waves, the data is uploaded to us and we process it. The smartwatch application works in the same way.”

Their core technology captures pulse waves with smartphone or wearables and analyzes it as accurately as an ECG. It is certified as a medical device class IIa, proven in large international clinical trials. This technology is the basis for the Preventicus business model, and they are, quite significantly, specialized as a certified medical device manufacturer, ISO 13485.

“In the early days we had a few people who did the programming, half of them did some quality checks, etcetera…but nowadays we have almost one test and quality assurance people per programmer, dedicated to all documentation and making everything according to ISO standards, the whole company works according to those standards.”

“Thanks to you and your network, you brought together fantastic people!”

Much of the investment into Preventicus goes towards clinical validation progress, and the company has seen a remarkable impact since they were awarded the SME Instrument Phase 2 grant. This impact has been felt not only their business expansion and hiring, but in becoming more reputable and gaining strategic connections around the European Union. The funding has been far more impactful beyond the money, and with the commitment from Horizon 2020 access to experts and the acceleration of business strategies has become a reality. Collaborating with Catalyze, Dr. Huebner also noted, was instrumental in achieving their success with SME Instrument Phase II and Eurostars, “Thanks to you and your network, you brought together fantastic people!

Finally, and quite notably, with the advantages of placing a Horizon 2020 grant, Preventicus is now more able to enter the “more attractive” German public health insurance market. Initially working with private insurance, the company is angling to reach a broader population. With over a hundred insurance companies in Germany, there are only 7-8 million privately insured individuals, while 72 million Germans are covered under public agencies.

It’s an absolutely prestigious project, and allows me to have a very good connection to the AF key opinion leaders in Europe.”

Awarded grant: Horizon2020- SME Instrument Phase II 

For more information about Preventicus: https://www.preventicus.com/en/

ZonMw and Zorginstituut Nederland release “Veelbelovende Zorg” subsidy for research and care of medical innovations to be allowed in the standard care package

ZonMw and Zorginstituut Nederland release “Veelbelovende Zorg” subsidy for research and care of medical innovations to be allowed in the standard care package

25-02-2019 Last week Catalyze attended the information day for the new call “Veelbelovende Zorg”, tender released by a collaboration of ZonMW and ZIN. This tender is the next program following on the “Voorwaardelijk Toelating”. The aim of the tender is to assist in the uptake of medical technologies and medication in the reimbursement model for… Continue Reading

Labonovum – simplifying laboratory analysis for patients

Labonovum – simplifying laboratory analysis for patients

Interview with Dennis Poland, Chief Innovation Officer (CIO) of Labonovum novum (plural novums or nova) A new feature, a novelty. Despite great advancements in clinical analysis laboratory for the past half century, not much has changed for patients – who still have to endure the same procedures to collect blood for analysis. Labonovum has recently been awarded €3 million with… Continue Reading

Press Release: iPSpine Kick-off Meeting

Press Release: iPSpine Kick-off Meeting

Amsterdam, 13 February 2019 On February 12th and 13th, the kick-off of an international, 15-million-euro, 20-partner project titled iPSpine (Induced pluripotent stem cell-based therapy for spinal regeneration) was held in Utrecht, The Netherlands. This 5-year project falls under the European Union’s Horizon 2020 programme to fund research that improves knowledge, testing, and exploitation platforms that address… Continue Reading

Catalyze and Health Valley announce strategic partnership to bring innovations to patients faster

Catalyze and Health Valley announce strategic partnership to bring innovations to patients faster

Amsterdam, 30 January 2019 Catalyze – a market leader in obtaining funding for life science innovations – joins forces with the healthcare innovation network Health Valley, in a strategic partnership aimed at bringing innovations to patients faster. Health Valley is the largest network of healthcare innovations in the Netherlands. Within the Health Valley network, companies,… Continue Reading

Accelerating Swiss innovations to market with strategic collaboration

Accelerating Swiss innovations to market with strategic collaboration

Amsterdam, 29 January 2019 Catalyze announces collaboration with Biopôle, providing dedicated services to members towards better access to non-dilutive funding opportunities. Catalyze is an expert in obtaining non-dilutive funding for life science innovations. Catalyze provides clients and partners with the necessary help in obtaining funding for their R&D projects, supporting them as well with services… Continue Reading

iPSpine – the veterinarian trying to solve the problem of low back pain

iPSpine – the veterinarian trying to solve the problem of low back pain

Interview with Professor Marianna Tryfonidou, from the Faculty of Veterinary Medicine of the Utrecht University The iPSpine project was recently awarded €15 million under the Horizon 2020 programme, towards researching a solution for chronic lower back pain. The huge public-private consortium is comprised of 20 partners, and is coordinated by the Faculty of Veterinary Medicine… Continue Reading

Financial aid for Danish applicants to European research and innovation: EUopSTART

Financial aid for Danish applicants to European research and innovation: EUopSTART

14-12-2018 Danish SMEs looking to apply to European research and innovation programmes can receive financial aid to prepare their grant application, including expenses in external assistance. With the EUopSTART programme, you can receive funding for external assistance to your application to programmes such as ERC, SME Instrument, Fast Track to Innovation and Eurostars. EUopSTART The… Continue Reading

Thinking about starting your own biotech company?

Thinking about starting your own biotech company?

12-12-2018 by Benjamin Sieters You are an academic researcher with a brilliant idea or some very promising results in your recent experiments. Now you’re thinking of starting your own biotech company to actually bring your invention from the lab to the market. Making the step from academic research to biotech entrepreneurship Here are some aspects… Continue Reading

Added value Catalyze

Why choose Catalyze?


Scientific & academic

experts

Team of consultants with scientific and academic excellence (PhD, MD)

Commercial

experts

Consultants with experience in translating research into commercial products

Life sciences

biotechnology

Specialized in life sciences, biotechnology and medical technology.

Strong

network

Strong network of reliable and professional partners in the field.